Increase in Venous Complications Associated With Etomidate Use During a Propofol Shortage: An Example of Clinically Important Adverse Effects Related to Drug Substitution

REFERENCES

1. ↵
   1. Doenicke A.

   (1973) Clinical experimental studies and first report on clinical experience with a new IV hypnotic, 22–25, Proceedings of the 6th International Refresher Course on Clinical Anesthesiology. Vienna, May 21-25.
2. ↵
   1. Doenicke A. W.,
   2. Roizen M. F.,
   3. Kugler J.,
   4. Kroll H.,
   5. Foss J.,
   6. Ostwald P.

   (1999) Reducing myoclonus after etomidate. Anesthesiology 90(1):113–119, pmid:9915320.

   OpenUrlCrossRefPubMedWeb of Science
3. ↵
   1. Holdcroft A.,
   2. Morgan M.,
   3. Whitwam J. G.,
   4. Lumley J.

   (1976) Effect of dose and premedication on induction complications with etomidate. Br J Anaesth 48(3):199–205, pmid:1259885.

   OpenUrlCrossRefPubMedWeb of Science
4. ↵
   1. Doenicke A.,
   2. Roizen M. F.,
   3. Nebauer A. E.,
   4. Kugler A.,
   5. Hoernecke R.,
   6. Beger-Hintzen H.

   (1994) A comparison of two formulations for etomidate, 2-hydroxypropyl-beta-cyclodextrin (HPCD) and propylene glycol. Anesth Analg 79(5):933–939, pmid:7978412.

   OpenUrlPubMedWeb of Science
5. ↵
   1. Doenicke A. W.,
   2. Roizen M. F.,
   3. Hoernecke R.,
   4. Lorenz W.,
   5. Ostwald P.

   (1999) Solvent for etomidate may cause pain and adverse effects. Br J Anaesth 83(3):464–466, pmid:10655920.

   OpenUrlCrossRefPubMedWeb of Science
6. ↵
   1. Zacharias M.,
   2. Clarke R. S.,
   3. Dundee J. W.,
   4. Johnston S. B.

   (1979) Venous sequelae following etomidate. Br J Anaesth 51(8):779–783, pmid:497076.

   OpenUrlCrossRefPubMedWeb of Science
7. ↵
   1. Bedichek E.,
   2. Kirschbaum B.

   (1991) A case of propylene glycol toxic reaction associated with etomidate infusion. Arch Intern Med 151(11):2297–2298, pmid:1953236.

   OpenUrlCrossRefPubMedWeb of Science
8. ↵
   1. Demey H. E.,
   2. Daelemans R. A.,
   3. Verpooten G. A.,
   4. et al.

   (1988) Propylene glycol-induced side effects during intravenous nitroglycerin therapy. Intensive Care Med 14(3):221–226, pmid:3132492.

   OpenUrlCrossRefPubMedWeb of Science
9. ↵
   1. Decousus H.,
   2. Epinat M.,
   3. Guillot K.,
   4. Quenet S.,
   5. Boissier C.,
   6. Tardy B.

   (2003) Superficial vein thrombosis: risk factors, diagnosis, and treatment. Curr Opin Pulm Med 9(5):393–397, pmid:12904709.

   OpenUrlCrossRefPubMedWeb of Science
10. ↵
    1. Hyers T. M.,
    2. Agnelli G.,
    3. Hull R. D.,
    4. et al.

    (2001) Antithrombotic therapy for venous thromboembolic disease. Chest 119((1 Suppl)):176S–193S, pmid:11157648.

    OpenUrlCrossRefPubMedWeb of Science
11. ↵
    1. Doenicke A.,
    2. Kugler A.,
    3. Vollmann N.,
    4. Suttmann H.,
    5. Taeger K.

    (1990) [Etomidate using a new solubilizer. Experimental clinical studies on venous tolerance and bioavailability]. Anaesthesist 39(10):475–480, pmid:2278365, German.

    OpenUrlPubMedWeb of Science
12. ↵
    1. Nyman Y.,
    2. Von Hofsten K.,
    3. Palm C.,
    4. Eksborg S.,
    5. Lönnqvist P. A.

    (2006) Etomidate-Lipuro is associated with considerably less injection pain in children compared with propofol with added lidocaine. Br J Anaesth 97(4):536–539, pmid:16914464.

    OpenUrlCrossRefPubMedWeb of Science
13. ↵
    1. Rühmann I.,
    2. Maier C.

    (1990) [The modification of injection pain and the incidence of thrombophlebitis following etomidate]. Anasth Intensivther Notfallmed 25((Suppl 1)):31–33, pmid:2178488, German.

    OpenUrlPubMed
14. ↵
    1. Yavascaoglu B.,
    2. Kaya F. N.,
    3. Ozcan B.

    (2007) Esmolol pretreatment reduces the frequency and severity of pain on injection of rocuronium. J Clin Anesth 19(6):413–417, pmid:17967668.

    OpenUrlCrossRefPubMedWeb of Science
15. ↵
    1. Ganta R.,
    2. Verma R.

    (1989) Pain on injection and venous sequelae following two formulations of etomidate. Eur J Anaesthesiol 6(6):431–434, pmid:2684661.

    OpenUrlPubMed